Print

Ad26.ENVA.01

A Phase 1 Randomized, Double-Blind, Placebo Controlled Dose Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Adenovirus Serotype 26 HIV-1 Vaccine (Ad26.ENVA.01) in Healthy, HIV-1 Uninfected Adults

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) February 01, 2008
Ad26.EnvA-01 Ad26 Env A
Ad26.EnvA-01 Viral Vector - Adeno
USA 48
NCT00618605
http://clinicaltrials.gov/ct2/show/NCT00618605